Navigation Links
Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Date:10/14/2008

DURHAM, N.C., Oct. 10 /PRNewswire/ -- Regado Biosciences, Inc., announced today the Company has completed enrollment in the Phase IIa clinical study of its REG1 Anticoagulation System in patients undergoing elective percutaneous coronary intervention (PCI). REG1 is a two-component system composed of an aptamer-based anticoagulant, RB006, and its matched, active reversal agent, RB007, which specifically binds to and neutralizes RB006. The Phase IIa study (REVERSAL-PCI) is designed to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon angioplasty dilatation and stenting on patients at low risk for complications associated with therapy-related bleeding or heart attack.

REVERSAL-PCI, a multi-center, open-label, randomized clinical study, has enrolled a total of 26 patients. All patients were pretreated with clopidogrel and aspirin to inhibit platelet activity and were then randomized to receive either REG1 or unfractionated heparin. In patients treated with the REG1 System, RB006 was used as the sole anticoagulant during the procedure. Following the procedure, RB007 was used to reverse the effects of RB006 with the goal of facilitating early sheath removal. Primary procedural success in the trial is defined by the absence of significant bleeding events up to hospital discharge or 48 hours post stenting, and by the absence of death, nonfatal heart attack, or need to repeat revascularization up to day 14.

David J. Mazzo, Ph.D., President and Chief Executive Officer of Regado Biosciences, stated, "The Phase IIa trial is designed to build on extensive Phase I results demonstrating, among other things, that RB006 safely and effectively inhibited the activity of factor IXa, an essential blood clotting protein, and that RB007 rapidly, safely and specifically reversed the activity of RB006. We are pleased to have reached this milestone in our clinical program and look forward to continued progress in the comi
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
2. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
5. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
6. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
7. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
8. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
11. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- A study using a relatively new imaging tool, ... the composition of carotid artery disease and has the ... disease, a leading cause of stroke. ... 2010 and May 2012, was featured in the June ... College of Cardiology (JACC) Cardiovascular Interventions. Interventional cardiologist ...
(Date:9/30/2014)... Sept. 30, 2014 BioStructures, LLC has ... Association of Tissue Banks (AATB), it was announced ... Officer. Accreditation follows an intensive nine-month ... trained AATB inspector.  It establishes that the level ... facility meets or exceeds the standards set by ...
(Date:9/30/2014)... 30, 2014 The report based ... Size, Share, Growth and Forecast, 2007 - 2017," elaborated ... USD 20.8 billion in 2012 and is further expected ... a CAGR of 7.3% from 2012 to 2017. ... health purposes, especially to prevent chronic diseases that may ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... Pharma,s eFlow,electronic nebulizer was included in Gilead,s (Nasdaq: ... to the U.S. Food and Drug Administration,(FDA) for ... mg,three times daily). Aztreonam lysine for inhalation, delivered ... people with cystic fibrosis,(CF) who have pulmonary Pseudomonas ...
... large, randomized Phase III trials of VELCADE in front-line, ... ... Mass., Nov. 26 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) today ... studies are scheduled to be,featured at the 49th ASH Annual Meeting ...
Cached Medicine Technology:PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation 2PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 2New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 4New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 5New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 6
(Date:9/30/2014)... no stranger to the children of Tanzania. What is ... clinical services, including reliable diagnosis and evidence-based treatments. There ... use in Swahili, a major language of the region. ... University and the University of Georgia (UGA) describe a ... sites in the country and found to be effective ...
(Date:9/30/2014)... 2014 Integrated Medicine Alliance , ... another new medical specialty practice through a unique partnership ... will be located within the company’s Shrewsbury location and ... Isaac Tawfik of American Heart Center, P.C., a highly ... will offer Integrated Medicine Alliance patients top notch cardiovascular ...
(Date:9/30/2014)... September 30, 2014 Glycodrive , ... Nutraceuticals designed to help maximize lean, strong muscle growth ... body’s absorption of glucose has caught the attention of ... main purpose behind Glycodrive is to help the body ... reports Michaels. “Carbs are essential in the muscle-building process, ...
(Date:9/30/2014)... 2014 VisitandCare.com reports that ... gone up more than 79 percent in 2014, marking ... also reported total revenue tripled for its entirety of ... professional strategy has allowed them to partner with ... patient comfort and privacy — with state-of-the-art surgical atmospheres ...
(Date:9/30/2014)... 2014 A group of Americans is headed ... epidemic that, left unchecked, could create a catastrophic, global pandemic. ... to Africa. John Rogers, the Executive Director the Eugene Bell ... fight a disease most think mankind conquered long ago: tuberculosis. ... ago is on the comeback in several countries - what’s ...
Breaking Medicine News(10 mins):Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2
... program delivered by over 500 peer volunteers significantly reduces ... researcher Dr. Janusz Kaczorowski told the Canadian Stroke Congress ... Program (CHAP), family physicians in 20 mid-sized Ontario communities ... assessment sessions held at local pharmacies over a 10 ...
... British Columbia (June 7, 2010) Researchers from the ... University of British Columbia today released a comprehensive study ... HIV treatment would create significant benefits for individuals infected ... peer-reviewed mathematical modeling study, published in the research journal ...
... Susan G. Komen for the Cure has appointed V. ... Council. Jordan, a member of the National Academy of ... department of oncology at the Lombardi Comprehensive Cancer Center at ... appointment to the Komen Scientific Advisory Council is reserved for ...
... WASHINGTON, June 7, 2010 Those social drinkers who order ... default "well" liquor. Are they just vodka snobs, who pay ... possibly taste much different than its $6 counterpart? Or is ... claim to taste in America,s favorite hard liquor? ...
... survivors diagnosed later with non-melanoma skin cancer may be ... 15 years, according to research led by St. Jude ... survivors in this Childhood Cancer Survivor Study (CCSS) who ... developed another more aggressive cancer within 15 years, said ...
... in German . Early detection is the ... lump turns out to be a malignant tumor. To find ... biopsy and examine the removed tissue under the microscope. This ... also highly time consuming. Research scientists at the Fraunhofer Institute ...
Cached Medicine News:Health News:A good CHAP reduces rates of heart disease and stroke in communities. 2Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 2Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 3Health News:Susan G. Komen for the Cure awards grant to Lombardi's V. Craig Jordan 2Health News:Susan G. Komen for the Cure awards grant to Lombardi's V. Craig Jordan 3Health News:Susan G. Komen for the Cure awards grant to Lombardi's V. Craig Jordan 4Health News:Brand preference may be in the drink, not in the head 2Health News:Non-melanoma skin cancer may help identify survivors at increased risk for future cancers 2Health News:Detecting tumors faster 2
... single use loading unit (SULU), the EEA™ ... staples., ,Immediately after staple formation, a ... excess tissue, thus creating a circular anastomosis. ... handles firmly as far as they will ...
... The Scantibodies Calcitonin Immunoassay is a ... of calcitonin. Two different goat polyclonal antibodies ... affinity chromatography to be specific for well-defined ... the quantitative determination of Calcitonin in human ...
... in the parafollicular C-cells of the thyroid ... The major action of calcitonin is to ... activity, resulting in decreased mobilization of calcium ... evident in conditions associated with high levels ...
Calcitonin RIA Kit...
Medicine Products: